These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. Sundkvist G; Armstrong FM; Bradbury JE; Chaplin C; Ellis SH; Owens DR; Rosén I; Sönksen P J Diabetes Complications; 1992; 6(2):123-30. PubMed ID: 1611136 [TBL] [Abstract][Full Text] [Related]
30. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187 [TBL] [Abstract][Full Text] [Related]
31. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Boulton AJ; Levin S; Comstock J Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323 [TBL] [Abstract][Full Text] [Related]
32. Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function. Sundkvist G; Lilja B; Rosén I; Agardh CD Acta Med Scand; 1987; 221(5):445-53. PubMed ID: 3111179 [TBL] [Abstract][Full Text] [Related]
33. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors. Jacobson M; Sharma YR; Cotlier E; Hollander JD Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448 [TBL] [Abstract][Full Text] [Related]
34. Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study. Jespersen J; Gram J; Christensen JE Haemostasis; 1986; 16(6):453-7. PubMed ID: 3108105 [TBL] [Abstract][Full Text] [Related]
35. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499 [TBL] [Abstract][Full Text] [Related]
36. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Handelsman DJ; Turtle JR Diabetes; 1981 Jun; 30(6):459-64. PubMed ID: 6785131 [TBL] [Abstract][Full Text] [Related]
37. The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes. Malone JI; Lowitt S; Salem AF; Miranda C; Korthals JK; Carver J Metabolism; 1996 Jul; 45(7):902-7. PubMed ID: 8692029 [TBL] [Abstract][Full Text] [Related]
38. Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Preliminary report. Culebras A; Alió J; Herrera JL; López-Fraile MI Arch Neurol; 1981 Feb; 38(2):133-4. PubMed ID: 6781454 [No Abstract] [Full Text] [Related]
39. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications]. Hotta N; Sakamoto N Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677 [No Abstract] [Full Text] [Related]